CNSX:ATT

Abattis Bioceuticals Competitors

Add
Compare
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
VolumeN/A
Average Volume1.42 million shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Abattis Bioceuticals (CNSX:ATT) Vs. RIV, WLLW, LABS, KHRN, DN, and META

Should you be buying ATT stock or one of its competitors? Companies in the industry of "drug manufacturers—specialty & generic" are considered alternatives and competitors to Abattis Bioceuticals, including RIV Capital (RIV), Willow Biosciences Inc. (WLLW.TO) (WLLW), MediPharm Labs (LABS), Khiron Life Sciences (KHRN), Delta 9 Cannabis (DN), and Meta Growth (META).

RIV Capital (TSE:RIV) and Abattis Bioceuticals (CNSX:ATT) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, analyst recommendations, dividends, earnings, risk, valuation and institutional ownership.

Earnings & Valuation

This table compares RIV Capital and Abattis Bioceuticals' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
RIV CapitalC$15.44 million21.93C$-106,223,568.00C($0.76)-3.19
Abattis BioceuticalsN/AN/AN/AN/AN/A

Abattis Bioceuticals has lower revenue, but higher earnings than RIV Capital.

Analyst Ratings

This is a summary of current ratings and recommmendations for RIV Capital and Abattis Bioceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
RIV Capital01002.00
Abattis Bioceuticals0000N/A

RIV Capital currently has a consensus target price of C$4.00, suggesting a potential upside of 65.29%.

Profitability

This table compares RIV Capital and Abattis Bioceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
RIV CapitalN/AN/AN/A
Abattis BioceuticalsN/AN/AN/A

Summary

RIV Capital beats Abattis Bioceuticals on 1 of the 1 factors compared between the two stocks.

Willow Biosciences Inc. (WLLW.TO) (TSE:WLLW) and Abattis Bioceuticals (CNSX:ATT) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, risk, analyst recommendations, earnings, dividends and institutional ownership.

Profitability

This table compares Willow Biosciences Inc. (WLLW.TO) and Abattis Bioceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Willow Biosciences Inc. (WLLW.TO)N/AN/AN/A
Abattis BioceuticalsN/AN/AN/A

Analyst Recommendations

This is a summary of current recommendations for Willow Biosciences Inc. (WLLW.TO) and Abattis Bioceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Willow Biosciences Inc. (WLLW.TO)0000N/A
Abattis Bioceuticals0000N/A

Willow Biosciences Inc. (WLLW.TO) currently has a consensus price target of C$2.25, suggesting a potential upside of 58.45%.

Valuation & Earnings

This table compares Willow Biosciences Inc. (WLLW.TO) and Abattis Bioceuticals' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Willow Biosciences Inc. (WLLW.TO)C$10,000.0017,504.06C$-51,032,952.00C($0.41)-3.43
Abattis BioceuticalsN/AN/AN/AN/AN/A

Abattis Bioceuticals has lower revenue, but higher earnings than Willow Biosciences Inc. (WLLW.TO).

Summary

Willow Biosciences Inc. (WLLW.TO) beats Abattis Bioceuticals on 1 of the 1 factors compared between the two stocks.

MediPharm Labs (TSE:LABS) and Abattis Bioceuticals (CNSX:ATT) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, earnings, profitability, analyst recommendations, institutional ownership, valuation and dividends.

Profitability

This table compares MediPharm Labs and Abattis Bioceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
MediPharm LabsN/AN/AN/A
Abattis BioceuticalsN/AN/AN/A

Analyst Ratings

This is a summary of recent ratings and price targets for MediPharm Labs and Abattis Bioceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
MediPharm Labs02023.00
Abattis Bioceuticals0000N/A

MediPharm Labs presently has a consensus target price of C$1.53, suggesting a potential upside of 194.23%.

Valuation and Earnings

This table compares MediPharm Labs and Abattis Bioceuticals' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MediPharm LabsC$36.01 million3.72C$-123,815,040.00C($0.48)-1.08
Abattis BioceuticalsN/AN/AN/AN/AN/A

Abattis Bioceuticals has lower revenue, but higher earnings than MediPharm Labs.

Summary

MediPharm Labs beats Abattis Bioceuticals on 2 of the 2 factors compared between the two stocks.

Khiron Life Sciences (CVE:KHRN) and Abattis Bioceuticals (CNSX:ATT) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, earnings, profitability, analyst recommendations, institutional ownership, valuation and dividends.

Profitability

This table compares Khiron Life Sciences and Abattis Bioceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Khiron Life SciencesN/AN/AN/A
Abattis BioceuticalsN/AN/AN/A

Valuation and Earnings

This table compares Khiron Life Sciences and Abattis Bioceuticals' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Khiron Life SciencesC$8.01 million10.69C$-39,493,921.00C($0.26)-2.17
Abattis BioceuticalsN/AN/AN/AN/AN/A

Abattis Bioceuticals has lower revenue, but higher earnings than Khiron Life Sciences.

Analyst Ratings

This is a summary of recent ratings and price targets for Khiron Life Sciences and Abattis Bioceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Khiron Life Sciences0000N/A
Abattis Bioceuticals0000N/A

Khiron Life Sciences presently has a consensus target price of C$1.20, suggesting a potential upside of 110.53%.

Summary

Khiron Life Sciences beats Abattis Bioceuticals on 1 of the 1 factors compared between the two stocks.

Delta 9 Cannabis (TSE:DN) and Abattis Bioceuticals (CNSX:ATT) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, profitability, valuation, analyst recommendations, institutional ownership and risk.

Profitability

This table compares Delta 9 Cannabis and Abattis Bioceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Delta 9 CannabisN/AN/AN/A
Abattis BioceuticalsN/AN/AN/A

Valuation & Earnings

This table compares Delta 9 Cannabis and Abattis Bioceuticals' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Delta 9 CannabisC$52.05 million1.16C$-7,346,808.00C($0.07)-8.19
Abattis BioceuticalsN/AN/AN/AN/AN/A

Abattis Bioceuticals has lower revenue, but higher earnings than Delta 9 Cannabis.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Delta 9 Cannabis and Abattis Bioceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Delta 9 Cannabis00014.00
Abattis Bioceuticals0000N/A

Delta 9 Cannabis currently has a consensus target price of C$1.24, suggesting a potential upside of 110.17%.

Summary

Delta 9 Cannabis beats Abattis Bioceuticals on 2 of the 2 factors compared between the two stocks.

Abattis Bioceuticals (CNSX:ATT) and Meta Growth (CVE:META) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, analyst recommendations, dividends, earnings and profitability.

Valuation and Earnings

This table compares Abattis Bioceuticals and Meta Growth's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Abattis BioceuticalsN/AN/AN/AN/AN/A
Meta GrowthC$60.96 million0.54C$-50,412,840.00C($0.21)-0.66

Abattis Bioceuticals has higher earnings, but lower revenue than Meta Growth.

Profitability

This table compares Abattis Bioceuticals and Meta Growth's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Abattis BioceuticalsN/AN/AN/A
Meta GrowthN/AN/AN/A

Analyst Ratings

This is a breakdown of recent ratings for Abattis Bioceuticals and Meta Growth, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Abattis Bioceuticals0000N/A
Meta Growth0000N/A

Summary

Meta Growth beats Abattis Bioceuticals on 1 of the 1 factors compared between the two stocks.


Abattis Bioceuticals Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
RIV
RIV Capital
0.8$2.42flatC$338.68 millionC$15.44 million-3.19News Coverage
Gap Up
WLLW
Willow Biosciences Inc. (WLLW.TO)
1.1$1.42flatC$175.04 millionC$10,000.00-3.43Gap Up
LABS
MediPharm Labs
1.3$0.52flatC$134.13 millionC$36.01 million-1.08Gap Up
KHRN
Khiron Life Sciences
0.9$0.57flatC$67.34 millionC$8.01 million-2.17
DN
Delta 9 Cannabis
1.4$0.59flatC$60.20 millionC$52.05 million-8.19News Coverage
Gap Down
META
Meta Growth
0.8$0.14flatC$36.69 millionC$60.96 million-0.66Gap Up
NRTH
48North Cannabis
0.7$0.20flatC$36.44 millionC$17.36 million-0.76Gap Down
CSI
(CSI)
0.6N/AN/A$0.00N/A0.00High Trading Volume
Gap Up
BAMM
28896
0.5N/AN/A$0.00N/A0.00High Trading Volume
AGRA
Agraflora Organics International
1.4N/AN/A$0.00N/A0.00High Trading Volume
News Coverage
GRIN
Grindrod Shipping
1.7N/AN/A$0.00N/A0.00High Trading Volume
IMCC
IM Cannabis
0.0N/AN/A$0.00N/A0.00High Trading Volume
PULL
Mind Cure Health
1.7N/AN/A$0.00N/A0.00High Trading Volume
SPR
Spirit AeroSystems
0.5N/AN/A$0.00N/A0.00High Trading Volume
News Coverage
BUZZ
VanEck Vectors Social Sentiment ETF
1.0N/AN/A$0.00N/A0.00High Trading Volume
VIDA
Vidaroo
0.5N/AN/A$0.00N/A0.00High Trading Volume
This page was last updated on 4/10/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.